Liisa Bayko, MBA.
BERKELEY HEIGHTS, N.J.—Kalaris Therapeutics, Inc. (Nasdaq: KLRS), a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for common retinal diseases has announced the appointment of Liisa Bayko, MBA, as chief financial officer, effective immediately. The company said Bayko’s hire as CFO supports its continued growth as it enrolls its phase 1b/2 study of TH103 for treatment of naïve neovascular age-related macular degeneration (nAMD) patients. “I am delighted to welcome Liisa to our team,” said Andrew Oxtoby, president and CEO of Kalaris Therapeutics.
Oxtoby said, “Liisa has extensive experience in assessing and valuing biotechnology companies, engaging the investor community, and navigating capital markets. She will be a valuable addition to our leadership team and will support Kalaris’ evolution as we advance clinical development efforts.”
Bayko brings more than two decades of experience in biotechnology finance, strategy and capital markets. She most recently served as managing director and senior biotechnology analyst at Evercore ISI. Prior to Evercore, Bayko was a senior biotechnology analyst at JMP Securities, where she covered a broad range of therapeutic areas and emerging drug development platforms. She holds a bachelor’s of science degree in life sciences from Queen’s University, an M.Sc. in medical biophysics from the University of Toronto, and an MBA from the Kellogg School of Management at Northwestern University.
“I am excited to join the Kalaris Therapeutics’ leadership team and look forward to helping the company achieve its mission to transform the lives of patients with retinal diseases,” said Bayko.
In March of this year, Kalaris reported a net loss of $43.4 million for full-year 2025, a reduction from the net loss of $69.2 million recorded for the year ended December 31, 2024.
